Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3 -Mutated AML.
Nicholas James ShortNaval G DaverCourtney D D DiNardoTapan Mahendra KadiaLewis Fady NasrWalid MacaronMusa YilmazGautam BorthakurGuillermo Montalban-BravoGuillermo Garcia ManeroGhayas C IssaKelly Sharon ChienElias J JabbourCedric NasnasXuelin HuangWei QiaoJairo MatthewsChristopher J StojanikKeyur Pravinchandra PatelRegina AbramovaJennifer ThankachanMarina Y KonoplevaHagop M KantarjianFarhad RavandiPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
-mutated AML. Myelosuppression was manageable with mitigative dosing strategies.